Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 12, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It is a regulatory disclosure regarding equity plan transactions rather than a financial results report.
Material Changes
The document details an increase in notional interests in Ordinary Shares and American Depositary Receipts (ADRs) for specific directors and PDMRs. This increase resulted from the notional re-investment of the dividend paid to shareholders on April 6, 2006.
- Transaction Date: April 11, 2006 (Notification date)
- Share Price: GBP 14.66 per Ordinary Share
- ADR Price: $51.14 per ADR
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the mechanics of the Performance Share Plan dividend re-investment.
Unusual Items: The filing notes that notional dividends accrued will be paid out in proportion to the percentage of participants' holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors to Verify
- Verify the vesting schedule and conditions for the Performance Share Plan to understand when these notional holdings may convert to actual payouts.
- Confirm the total number of shares and ADRs held by the listed directors (e.g., Mr. R Bondy, Dr. J P Garnier, Mr. A Witty) to assess total executive compensation exposure.
- Review the dividend payment date of April 6, 2006, to correlate with the re-investment transaction.